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Abstract: The primary envelopment/de-envelopment of Herpes viruses during nuclear exit is poorly
understood. In Herpes simplex virus type-1 (HSV-1), proteins pUL31 and pUL34 are critical, while
pUS3 and some others contribute; however, efficient membrane fusion may require additional host
proteins. We postulated that vesicle fusion proteins present in the nuclear envelope might facilitate
primary envelopment and/or de-envelopment fusion with the outer nuclear membrane. Indeed,
a subpopulation of vesicle-associated membrane protein-associated protein B (VAPB), a known vesicle
trafficking protein, was present in the nuclear membrane co-locating with pUL34. VAPB knockdown
significantly reduced both cell-associated and supernatant virus titers. Moreover, VAPB depletion
reduced cytoplasmic accumulation of virus particles and increased levels of nuclear encapsidated
viral DNA. These results suggest that VAPB is an important player in the exit of primary enveloped
HSV-1 virions from the nucleus. Importantly, VAPB knockdown did not alter pUL34, calnexin or
GM-130 localization during infection, arguing against an indirect effect of VAPB on cellular vesicles
and trafficking. Immunogold-labelling electron microscopy confirmed VAPB presence in nuclear
membranes and moreover associated with primary enveloped HSV-1 particles. These data suggest
that VAPB could be a cellular component of a complex that facilitates UL31/UL34/US3-mediated
HSV-1 nuclear egress.
Keywords: nuclear envelope; nuclear membrane protein; herpes simplex virus-1 (HSV-1); vesicle
fusion protein (VFP); VAPB; nuclear egress
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1. Introduction
Herpesvirus genome replication and encapsidation occurs in the host cell nucleus. The capsids at
~120 nm cannot pass through nuclear pore complexes [1], and so must traverse the nuclear envelope
(NE) before virion maturation in the cytoplasm [2]. Capsids obtain a primary envelope from the inner
nuclear membrane (INM), resulting in access to the NE lumen. They then exit the lumen by fusing
with the outer nuclear membrane (ONM), leaving their primary envelope behind [3–5]. pUL31 and
pUL34 are key viral proteins for HSV-1 nuclear egress. They recruit host kinases to locally dissolve
the intermediate filament nuclear lamin polymer to allow nucleocapsid access to the INM [6–9] and
it has been suggested that they may promote vesiculation in vitro and in vivo [10,11]. Though its
specific function is not clear, HSV-1 pUS3 contributes to nuclear egress as primary enveloped particles
accumulate in the NE lumen when it is depleted [12–14]. This is also observed for a combined
knockdown of HSV-1 glycoproteins gB and gH that are also components of the final envelope [15,16].
However, as herpesviruses commonly co-opt host proteins [17,18] and cellular vesicle fusion requires
many players [19,20], it has been suggested that host proteins might cooperate with viral proteins for
efficient nuclear egress [21]. Several cellular proteins have been reported to be involved, including
CD98 heavy chain, its binding partner β-integrin, and p32. CD98/β-integrin are fusion regulatory
proteins and they accumulate at the nuclear membrane during HSV infection and interact with HSV-1
gB, gH, pUL31 and pUS3, all known to be involved in HSV de-envelopment [22]. p32 has been
proposed to cause disassembly of the nuclear lamina by interacting with ICP34.5 [23]. This would
indicate a role in primary envelopment but p32 can bind to HSV-1 pUL47, a major tegument protein,
and through this interaction relocate to the NE, suggesting instead a role in de-envelopment [24].
It has been clearly established that transmembrane proteins can translocate between the nuclear
membrane and the ER by a lateral diffusion mechanism [25–28]. Due to there being many connections
between the ONM and the ER and between the ONM and the nuclear pores, a protein in the ONM
could diffuse either to the ER or to the INM. Therefore, during HSV infection, any host proteins
facilitating egress that fuse with the ONM might be expected to be found in both the NE and the ER,
where they moreover might be observed to increase in abundance. Both INM proteins that become
part of the primary envelope and ONM proteins supporting de-envelopment should have a reasonable
likelihood of diffusing into the ER and so increasing in abundance there during an HSV-1 infection.
To test this and to search for candidate viral fusion facilitators, these membrane components were
prepared from mock versus HSV-1 infected cells and analyzed for proteins that both could be found in
the NE in uninfected cells and increase in the ER in infected versus uninfected cells. A subset of vesicle
fusion proteins (VFPs) were identified as possible fusion facilitators. We examined the role of the
most-enriched VFP, vesicle-associated membrane protein-associated protein B (VAPB). VAPB depletion
yielded reduced virus titers, and led to nuclear virion accumulation concomitant with a reduction
in cytoplasmic virions. A subpopulation of VAPB located at the NE co-localized in part with pUL34.
Nuclear virions, moreover, were stained for VAPB by immunogold-labelling electron microscopy.
These data suggest that VAPB is an important contributor to the HSV-1 life cycle and may facilitate
nuclear egress.
2. Materials and Methods
2.1. Cells and Viruses
HeLa and U20S cells were cultured in Dulbecco’s Modified Eagles Medium, 10% fetal calf serum,
50 µg/mL penicillin, 50 µg/mL streptomycin at 37 ◦C, 5% CO2. Wild-type HSV-1 was strain 17+.
A modified strain carrying genomic replacement of VP26-RFP (kindly provided by Frazer Rixon,
University of Glasgow, Glasgow, UK) was used for the experiment shown in Figure 1B, which visually
determined the optimized time to take infected cells for protein preparation. For infections, the virus
was adsorbed onto cells for 1 h at 37 ◦C.
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Figure 1. Optimization of conditions to isolate HSV‐1 infected MMs. (A) An expression timecourse of 
US3 and gC viral proteins was analyzed by Western blot to determine the optimal time to isolate HSV‐
1 infected MMs before significant secondary envelopment had occurred. Cell lysates from Hela cells 
infected at MOI = 10 were prepared at indicated times post‐infection. α‐tubulin was used as a loading 
control. (B) Fluorescence microscopy images of an HSV‐1 strain with VP26 capsid protein fused with 
RFP in Hela cells after 8, 9 and 10 hpi. At 8 hpi, most of the VP26 signal was located inside the nucleus 
of infected cells. At 9 hpi, cells started to show perinuclear localization of VP26. Scale bar, 10 µm. (C) 
Coomassie‐stained gel of mock‐infected NE, mock‐infected MM, and HSV‐1 infected MM fractions 
showed a clear difference in protein composition between NEs and MMs, but no notable visible 
differences between infected and mock‐infected MMs. (D) Western blot of fractions from (C) stained 
with ER and NE markers to determine fraction purity. Infected MMs are shown. The ER marker 
calnexin was present in both NE and MM fractions as expected, because the ONM is continuous with 
the ER and many proteins are shared. In contrast, the NE markers lamin A/C and Lap2β were absent 
from MMs. Similar amounts of total protein were loaded. (E) To test for possible Golgi contamination 
in the preps, the NE and MM fractions were blotted for Golgi marker GM‐130. Equal protein loading 
from HeLa cells confirmed that the antibody was working. (F) Ultrastructure of isolated MMs from 
HSV‐1 infected HeLa cells. Electron micrographs showed the characteristic single‐membrane structure 
of the MMs. Arrows point to electron‐dense symmetrical structures of around 100 nm diameter that 
probably represent primary viral particles with the bottom one likely lacking a packaged genome. 
Scale bars, 100 nm. 
2.2. Preparation of Fractions 
Nuclear envelopes (NEs) and microsomal membranes (MMs) were isolated from HeLa cells 
using established procedures [29]. For microsomes, we started with ~2 × 109 cells from 15 roller bottle 
cultures. The post‐nuclear supernatant was treated with 0.5 mM EDTA to inhibit metalloproteinases. 
Mitochondria and other debris were removed by pelleting 15 min at 10,000× g. Microsomes were 
floated through 1.86 M and 0.25 M sucrose layers by centrifugation in the SW28 rotor 4 h at 57,000× g, 
Figure 1. Optimization of conditions to isolate SV-1 infected MMs. (A) An expression timecourse
of US3 and gC viral proteins was analyzed by Western blot to determine the optimal time to isolate
HSV-1 infected MMs before significant secondary envelopment had occurred. Cell lysates from Hela
cells infected at MOI = 10 w re prepared t indicated times post-infection. α-tubulin was used as a
loading control. (B) Fluorescence microscopy i ages of an HSV-1 strain with VP26 capsid protein
fused with RFP in Hela cells after 8, 9 and 10 hpi. At 8 hpi, most of the VP26 signal was located inside
the nucleus of infected cells. At 9 hpi, cells started to show perinuclear localization of VP26. Scale
bar, 10 µm. (C) Coomassie-stained gel of mock-infected NE, mock-infected MM, and HSV-1 infected
MM fractions showed a clear difference i protein composition between NEs and MMs, but no notable
visible differences between infected and mock-infected MMs. (D) Western blot of fractions from (C)
stained with ER and NE markers to determine fraction purity. Infected MMs are shown. The ER marker
calnexin was present in both NE and MM fractions as expected, because the ONM is continuous with
the ER and any proteins are shared. In contrast, the NE markers lamin A/C and Lap2β were absent
from MMs. Similar amounts of total protein were loaded. (E) To test for possible Golgi contamination
in the preps, the NE and MM fractions were blotted for Golgi marker GM-130. Equal protein loading
from HeLa cells confirmed that the antibody was working. (F) Ultrastructure of isolated MMs from
HSV-1 infected HeLa cells. Electron micrographs showed the characteristic single-membrane structure
of the MMs. Arrows point to electron-dense symmetrical structures of around 100 nm diameter that
probably represent primary viral particles with the bottom one likely lacking a packaged g nome. Scale
bars, 100 nm.
2.2. Preparation of Fr ctions
Nuclear envelopes (NEs) and microsomal membranes (MMs) were isolated from HeLa cells using
established procedures [29]. For microsomes, we started with ~2 × 109 cells from 15 roller bottle
cultures. The post-nuclear supernatant was treated with 0.5 mM EDTA to inhibit metalloproteinases.
Mitochondria and other debris were removed by pelleting 15 min at 10,000× g. Microsomes
were floated through 1.86 M and 0.25 M sucrose layers by centrifugation in the SW28 rotor 4 h
at 57,000× g, 4 ◦C. Material between the layers was diluted 4-fold with 0.25 M SHKM (50 mM HEPES
pH 7.4, 25 mM KCl, 5 mM MgCl2, 1 mM DTT and 1.8 M sucrose) and pelleted at 152,000× g 1 h in
a type 45 Ti rotor (Beckman, Brea, CA, USA). NEs were extracted with 0.1 N NaOH, 10 mM DTT,
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pelleted at 150,000× g for 30 min, and washed 3× in H2O. MMs were washed in H2O without NaOH
extraction. The samples were divided for mass spectrometry and EM.
2.3. Mass Spectrometry
Pellets resuspended in 30 µL of 100 mM Tris-HCl pH 8.5, 8 M Urea were brought to 5 mM
Tris(2-Carboxylethyl)-Phosphine Hydrochloride (TCEP) and incubated for 30 min RT. Reduction and
alkylation used 10 mM chloroacetamide, 30 min in the dark. Endoproteinase Lys-C (Roche, Basel,
Switzerland) was added at 0.1 mg/mL and incubated for 6 h, 37 ◦C. Following dilution to 2 M Urea
with 100 mM Tris-HCl pH 8.5, 2 mM CaCl2, 0.1 mg/mL Trypsin, digestion was at 37 ◦C overnight.
5% formic acid quenched reactions and samples were centrifuged to remove undigested material.
The samples were analyzed by Multidimensional Protein Identification Technology (MudPIT) as
previously described [30,31] with pressure-loading onto microcapillary columns packed with 3 cm of
5-µm Strong Cation Exchange (Luna; Phenomenex, Torrance, CA, USA), followed by 1 cm of 5 µm C18
reverse phase (Aqua; Phenomenex, Macclesfield, UK). These were connected to 100 µm columns pulled
to a 5 µm tip containing 9 cm of reverse phase material. Peptides were separated on a Quaternary
Agilent 1100 HPLC using a 10-step chromatography run over 20 h at 200–300 nL/min. Eluting peptides
electrosprayed at 2.5 kV distal voltage into a LTQ linear ion trap mass spectrometer (Thermo Scientific,
Waltham, MA, USA) with a custom-made nano-LC electrospray-ionization source. Full MS spectra
were recorded on the peptides over 400 m/z to 1,600 m/z, followed by five tandem mass (MS/MS)
events, sequentially generated in a data-dependent manner on the first to fifth most intense ions
selected from the full MS spectrum (at 35% collision energy). Dynamic exclusion was enabled for 120 s.
RAW files extracted into ms2 files [32] using RawDistiller v1.0 [33] were queried for peptide
sequences using SEQUEST v.27 (rev.9) [34] against 55,691 human proteins (non-redundant NCBI
2014-02-04 release), plus 162 usual contaminants (e.g., keratin) and 77 NCBI RefSeq HSV-1 proteins.
To estimate false discovery rates (FDRs), each non-redundant sequence supplemented the database
after randomization, bringing the search space to 111,524 sequences. MS/MS spectra were searched
without specifying differential modifications, but +57 Da were added statically to cysteines to account
for carboxamidomethylation. No enzyme specificity was imposed and mass tolerance was set at 3 amu
for precursor ions and ±0.5 amu for fragment ions.
Results from different runs were compared using DTASelect and CONTRAST [35] with criterion
of DeltCn ≥ 0.08, XCorr ≥ 1.8 for singly-, 2.5 for doubly-, and 3.5 for triply-charged spectra, and a
maximum Sp rank of 10. Merging peptide hits from all analyses established a master protein list
(Table S1). Identifications mapping to randomized peptides estimated FDRs that averaged 0.72% for
proteins and 0.24% for peptides. Spectral-count based label free quantitation was used to estimate the
relative levels of the proteins detected by mass spectrometry in each sample. In shotgun proteomics,
the frequency of peptides being fragmented by the mass spectrometer (spectral counts) correlates
with the abundance of the proteins these peptides derive from. Because longer proteins tend to
generate more tryptic peptides, spectral counts are normalized by the protein molecular weight or
length, defining a “spectral abundance factor” (SAF), which is further normalized against the sum of
SAFs calculated for each protein/protein group detected in a sample. To deal with peptides shared
between multiple proteins, distributed Normalized Abundance Factors (dNSAFs) are calculated for
each non-redundant protein/protein group (Tables 1, 2 and S1), as described in [36]
dNSAFi =
dSAFi
∑Ni=1 dSAFi
with dSAFi =
uSpCi +
uSpCi
∑Mm=1 uSpCm
× sSpCij
Lengthi
in which shared spectral counts (sSpC) are distributed based on spectral counts unique to each protein
i (uSpC), divided by the sum of all unique spectral counts for the M protein isoforms that shared
peptide j with protein i.
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Table 1. Abundance of viral proteins identified in HSV-1 infected MMs.
Protein Unique Peptides Spectral Counts dNSAF Score ID’d in Padula Study
US6 Glycoprotein D 7 38 0.00303 YES
UL27 Glycoprotein B 14 62 0.00216 NO
UL44 Glycoprotein C 6 30 0.00185 NO
Nuclear egress membrane protein pUL34 4 15 0.00171 YES
Virion protein US2 4 14 0.00151 NO
Membrane protein UL45 2 7 0.00128 NO
UL49 Tegument protein VP22 4 11 0.00115 YES
UL19/VP5 Major capsid protein 18 46 0.00105 YES
UL48 Tegument protein VP16 6 16 0.00103 NO
UL50 Deoxyuridine triphosphatase 3 12 0.00102 NO
US8 Glycoprotein E 8 16 0.00091 NO
UL18/VP23 Capsid triplex subunit 2 4 9 0.00089 YES
UL46 Tegument protein VP11/12 7 19 0.00083 NO
UL47 Tegument protein VP13/14 7 14 0.00063 NO
UL10 Glycoprotein M 1 8 0.00053 NO
UL42 DNA pol processivity subunit 4 8 0.00052 NO
US7 Glycoprotein I 3 6 0.00048 NO
UL40 Ribonucleotide reductase subunit 2 3 5 0.00046 NO
Tegument protein UL7 3 4 0.00042 NO
UL22 Glycoprotein H 5 11 0.00041 NO
pUL31 Nuclear egress lamina protein 2 4 0.00041 NO
UL29/ICP8 Single-stranded DNA binding protein 7 15 0.00039 NO
UL39 Ribonucleotide reductase subunit 1 8 14 0.00039 NO
Tegument protein UL51 2 3 0.00039 NO
ICP4 10 15 0.00036 NO
US10 2 3 0.00030 NO
UL12 Deoxyribonuclease 4 6 0.00030 NO
UL54 Multifunctional expression regulator 3 4 0.00025 NO
UL24 1 2 0.00023 NO
US1/ICP22 2 3 0.00023 NO
UL41 Tegument host shutoff protein 2 3 0.00019 NO
Tegument protein UL21 1 3 0.00018 NO
UL26/VP24/VP21 Capsid maturation protease 2 3 0.00015 YES
UL39/VP19C Capsid triplex subunit 1 1 2 0.00014 YES
Tegument protein UL25 2 2 0.00011 NO
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Table 2. Peptide and spectral counts for VAPB proteins passing the candidate criteria.
HSV-1 Infected MMs Mock Infected MMs Mock Infected NEs
Protein Unique Peptides SpectralCounts dNSAF
HSV1 MMs:mockMMs
Ratio
Unique
Peptides
Spectral
Counts dNSAF MockNEs:MockMMs Ratio Unique Peptides Spectral Counts dNSAF
VAPB 2 7 0.002286 6.3 1 3 0.000363 9.0 2 8 0.003261
VAMP7 2 4 0.000702 4.9 1 2 0.000142 17.8 3 11 0.002523
RAB11B 7 49 0.007065 2.0 6 61 0.003560 3.4 7 65 0.012242
RAB9A 2 3 0.000469 1.9 1 4 0.000253 4.8 3 6 0.001226
RAB1A 4 35 0.005357 1.7 5 50 0.003093 11.9 5 184 0.036801
RAB18 8 23 0.003509 1.7 7 33 0.002038 22.1 8 226 0.045044
STX7 1 2 0.000241 1.7 1 3 0.000146 12.9 4 12 0.001888
RAB2A 4 17 0.002520 1.4 6 30 0.001800 6.1 9 57 0.011039
RAB35 3 17 0.002658 1.4 4 30 0.001899 1.4 3 13 0.002655
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2.4. Bioinformatics
Ratios of HSV-1 infected MMs:mock-infected MMs and mock-infected NE:mock-infected MM
were calculated from dNSAF values. Only proteins with an HSV-1 infected MMs:mock-infected MMs
ratio higher than 1.3 and detected in the mock infected NEs were selected. Gene ontology (GO)
analysis was performed in Ensembl BioMart. GO-terms and their corresponding child-terms were
retrieved from the mySQL database http://amigo.geneontology.org [37]: “vesicle-mediated transport”
(GO:0016192) “nucleocytoplasmic transport” (GO:0006913), “membrane organization” (GO:0061024),
“regulation of protein phosphorylation” (GO:0001932). Relative proportions of these classes were
calculated from the relative abundances of genes identified from each category, then compared to the
proportions of all human-encoded proteins considering the same categories.
2.5. siRNA Knockdown of VFPs
HeLa cells were transfected for 48 h with 50 nM final concentration siRNAs to VAPB, Rab1a and
Rab24 using JetPrime (Polyplus, New York, NY, USA). All siRNAs were Dharmacon (Lafayette,
CO, USA) SMARTpools, except VAPB where a proven single siRNA oligo (Sigma, St. Louis,
MO, USA) was used [38]. Control non-target siRNA was a scrambled firefly luciferase sequence
(5′-CGUACGCGGAAUACUUCGA-3′). Following transfection, total protein was extracted for Western
blot to determine knockdown or cells were infected with HSV-1 at MOI = 10 for the times indicated.
2.6. Rescue Experiments
VAPB was cloned from keratinocyte cDNA into pCDNA3.1 and desensitized to the siRNA by
changing CTTGGCTCTGGTGGTT to GTTTGCACTTGTCGTG using CloneAmp HiFi PCR Premix
(Clontech, Mountain View, CA, USA). Mutations were verified by Sanger sequencing. Other siRNAs
targeted 3′ untranslated regions, so mutagenesis was not required for their rescue constructs. HeLa
cells expressing rescue constructs were transfected with siRNA for 48 h, then infected with HSV-1
at MOI = 10 for 16 h. As indicated in the figure legends, either released virus was collected by
pelleting from the supernatant or cell-associated virus was collected after extensive washing followed
by pelleting cells. Titrations were carried out on U2OS cells as described [39]. U2OS cells were used for
titrations because they are the most optimized for virus entry and replication and thus enable better
measurement of the number of infectious particles.
2.7. Isolation of Nuclei and DNA Preparation for qPCR
Cells were scraped into 1 mL PBS then pelleted by centrifugation in an Eppendorf microfuge 1 min
at 8000× g, 4 ◦C and resuspended in 400 µL hypotonic Buffer A (10 mM Hepes, 1.5 mM MgCl2, 10 mM
KCl, 0.5 mM DTT, pH 7.9). Cells were lysed by 15 syringe passages through a 21-gauge needle following
15 min incubation on ice. The nuclei were pelleted by centrifugation then broken by sonication. Nuclei
were resuspended in DNase digestion buffer and incubated for 1 h, 37 ◦C using 10 units RQ DNAse 1
(Promega, Madison, WI, USA) followed by enzyme inactivation. DNase-resistant nuclear DNA was
prepared using a QiAamp DNA mini kit (Qiagen, Germantown, MD, USA) incorporating RNase and
proteinase K digestion.
2.8. qPCR
siRNA-transfected cells were infected with HSV-1 WT and supernatants or pellets
were collected at 16 hpi. Viral DNA was purified as above. qPCR was carried out
on an Applied Biosystem 7500 machine with TakyonTM Low Rox Probe MasterMix
dTTP Blue (Eurogentec, Liege, Belgium) using primers detecting gD HSV-1 sequence [40]
(Forward: 5′-CGGCCGTGTGACACTATCG-3′, Reverse:5′-CTCGTAAAATGGCCCCTCC-3′,
Probe: FAM-CCATACCGACCACACCGACGAACC-TAMRA) and a cellular GAPDH control
(Forward: 5′-CGCTCTCTGCTCCTCCTGTT-3′, Reverse:5′-CCATGGTGTCTGAGCGATGT-3′, Probe:
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5′-CAAGCTTCCCGTTCTCAGCC-3′). Serial dilutions of known-titer HSV-1 were used to create a standard
curve in genomes/mL.
2.9. Western Blotting
Proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and blocked
with 5% milk powder in PBS containing 0.1% Triton-X-100 (PBST) for 1 h, RT. Primary antibodies
were applied for 1–2 h, RT or overnight, 4 ◦C, washed in PBST, then incubated with anti-mouse
IgG or anti-rabbit IgG conjugated to horseradish peroxidase for 1 h. Following washing in PBST,
membranes were visualized either using ECL (GE Healthcare) and exposed to Kodak X-Omat S film
or analyzed directly on a LICOR Odyssey imager (LI-COR Biosciences, Lincoln, Ne, USA) using
antibodies conjugated to fluorescent markers. Antibodies: GM-130 (EP892Y, Abcam, Cambridge, UK),
GAPDH (E1C604-1, Enogene, Calnexin (SPA-860, Stressgen, San Diego, CA, USA), lamin A and C
(3262, 3931), Rab1a (Santa Cruz Biotechnology, Dallas, TX, USA), Rab24 (BD bioscience, San Jose, CA,
USA), gC (ab6509, Abcam, Cambridge, UK), VAPB mouse monoclonal antibody (66191-1, Proteintech,
Manchester, UK), and US3 (rabbit polyclonal) and UL34 (rabbit polyclonal) antibodies were kindly
provided by Dr. Thomas Mettenleiter and Dr. Barbara Klupp (Friedrich-Loeffler-Institut, Greifswald,
Germany). Dr. Christopher C.J. Miller (Kings College London, London, UK) kindly provided the
VAPB rabbit antibody.
2.10. Fluorescence In Situ Hybridization (FISH)
HeLa cells cultured on coverslips were washed in PBS prior to fixation in 4% para-formaldehyde,
1× PBS for 10 min at RT. Cells were permeabilized 6 min with 0.2% Triton-X-100 in PBS then
pre-equilibrated in 2× SCC and treated with RNase A (100 µg/mL) at 37 ◦C, 1 h. Following washing
in 2× SCC, cells on coverslips were dehydrated with a 70%, 85%, 100% ethanol series, then air dried,
heated to 70 ◦C and submerged into 85 ◦C preheated 70% formamide, 2× SSC (pH 7.0) for 18 min.
A second ethanol dehydration series was performed. 150–300 ng biotin-labelled probe was added in
hybridization buffer (50% formamide, 2× SSC, 1% Tween20, 10% Dextran Sulphate) containing 6 µg
human Cot1 DNA (Invitrogen, Waltham, MA, USA) and sheared salmon sperm DNA and incubated
at 37 ◦C, 24 h. An HSV-1 ICP27 plasmid was end-labelled. After incubation with this probe, coverslips
were washed 4 × 5 min in 4× SSC, 50 ◦C, followed by 4 × 5 min washes in 0.1× SSC, 65 ◦C, then
pre-equilibrated in 4× SSC, 0.1% Tween-20 and blocked with 4% BSA before incubating 30 min, RT with
Alexa Fluor® (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) conjugated-Steptavidin
antibodies and 4,6-diamidino-2 phenylindole, dihydrochloride (DAPI) at 2 µg/mL. Coverslips were
washed 3 times in 4× SSC, 0.1% Tween-20, 37 ◦C and mounted on slides in Vectashield (Vector Labs).
2.11. Fluorescence Microscopy
HSV-1 or mock-infected HeLa cells grown on coverslips were fixed 10 min in 3.7% formaldehyde
in PBS, then permeabilized for 5 min, RT with 0.2% Triton X-100. Blocking was with PBS containing
10% human serum, 10% donkey serum and 1% BSA,1 h, RT. Primary antibodies were applied for 1 h at
RT: VAPB (66191-1, mouse monoclonal, Proteintech, Manchester, UK; 1:200), US3 (rabbit polyclonal;
1:500) and pUL34 (rabbit polyclonal; 1:500); both rabbit antibodies were kindly provided by Thomas
Mettenleiter and Barbara Klupp (Friedrich-Loeffler-Institut, Greifswald, Germany). Following 1 h
incubation with Alexa-fluor secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove,
PA, USA; 1:1000) and 4′,6-diamidino-2-phenylindole (DAPI; 1:2000) in blocking buffer and washing,
the coverslips were mounted with Vectashield. All secondary antibodies were donkey minimal
cross-reactive conjugates to Alexa-fluor dyes matched to the Sedat quad filters used (488, 568, and 647)
to prevent signal bleedthrough and negative controls were generally done to further confirm lack of
cross-reactivity. Images were acquired on a Nikon TE-2000 microscope using a 1.45 NA 100× objective,
Sedat quad filter set, PIFOC Z-axis focus drive (Physik Instruments, Cranfield, UK), and a CoolSnapHQ
High Speed Monochrome CCD camera (Photometrics, Tucson, AZ, USA) run by Metamorph software.
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This provided a pixel size of 0.0645 µm2. For general widefield images shown in Figures 1B, 3B, 6B and
7A, an image was taken from a focus point at the midplane of the nucleus as this generally excludes
signal from any other staining above or below the nucleus and generally affords the widest view of the
ER as well outside the nucleus. For Figure 3E images, image stacks (0.2 µm steps) were deconvolved
using AutoquantX (Media Cybernetics, Rockville, MD, USA). Images in Figure 6A were taken using a
Zeiss LSM510 Meta confocal microscope. Micrographs were saved from source programs as 12-bit.tif
files and analyzed with Image Pro Plus software and/or prepared for figures using Photoshop CS6.
Images stained with the same antibodies were taken using identical settings and exposure times.
For FISH experiments, DAPI images were used as a mask in ImageJ to determine nuclear area, and the
total fluorescence intensity in the nucleus versus the whole cell was determined for >100 cells for each
condition. For NE:ER ratio quantification, original images were analyzed in ImageJ using the edge of a
DAPI image mask and taking 5 pixels in either direction to define NE fluorescence intensity. Given the
100–200 nm limit of resolution for standard (non-super resolution) fluorescence microscopy and the
architecture of the NE, this 300 nm distance from the edge of the DNA signal should capture the full
NE signal. ER fluorescence intensity was determined from pixels outside the NE ring and mean pixel
intensities were determined by dividing total intensities by area. The NE/ER value for >50 cells per
condition was determined and means plotted.
2.12. Electron Microscopy
MM pellets were washed in sterile H2O and fixed with 2.5% glutaraldehyde and 1% osmium
tetroxide, then dehydrated through a graded alcohol series and embedded in Epon 812. siRNA-treated
and HSV-infected HeLa cells were fixed with 2.5% glutaraldehyde in 2% sucrose, 0.05M Cacodylate
buffer, pH 7.2 overnight at 4 ◦C. Cells pelleted by centrifugation were fixed with 1% osmium tetroxide
(TAAB Labs, Aldermaston, UK) and stained for 1 h, RT with 2% aqueous uranyl acetate. Cells
were pelleted through 3% low melting temperature agarose (Geneflow, Lichfield, UK) at 45 ◦C.
The agarose was set at 4 ◦C and cell pellets were cut into ~1 mm cubes, then dehydrated through a
graded alcohol series (30–100%) and embedded in Epon 812 resin (TAAB Labs, Aldermaston, UK)
followed by polymerization for 3 days at 65 ◦C. 120 nm sections were cut with a UC6 ultramicrotome
(Leica Microsystems, Wetzlar, Germany) and examined in a JEOL 1200 EX II electron microscope,
recording images on a Gatan Orius CCD camera. Immunoelectron microscopy was performed using
the Tokuyasu method [41]. For imaging, a Hitachi H7600 TEM was used at 100 kV.
2.13. Data Availability
The mass spectrometry dataset [raw, peak, search, and DTASelect result files) can be obtained
from the MassIVE database via MSV000079886, from the ProteomeXchange via PXD004519, and from
the Stowers Original Data Repository at LIBPB-1083.
3. Results
3.1. Identification of Cellular Proteins Potentially Involved in Viral Egress
Cellular proteins involved in nuclear egress must be present and might even accumulate in the
NE during infection. Moreover, if they become part of the primary envelope and/or are involved
in de-envelopment fusion with the ONM, they may specifically accumulate in the ONM as nuclear
egress progresses and possibly also in the contiguous ER after fusion with the ONM. Although
their residence in both membranes could be brief due to recycling back to the INM, we reasoned
that a proteomics analysis of NE and ER membrane fractions may provide some clues as to the
types of cellular proteins that might take part in HSV nuclear egress. We analyzed HeLa nuclear
and ER (microsomal) membranes around the time of viral nuclear egress but before secondary
envelopment. pUS3, a serine/threonine viral kinase that contributes to primary envelope fusion
with the ONM, is expressed before primary envelopment/de-envelopment and peaks roughly when
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secondary enveloped particles are first detected [13,14]. By contrast, surface glycoprotein gC is
expressed later in infection. Western blotting showed that pUS3 began to be highly expressed at 9 h
post-infection (hpi), reaching maximal levels by 12 hpi (Figure 1A). At this time, gC was only becoming
detectable. A second analysis found that in infected HeLa cells, RFP-labeled capsid protein VP26
was in punctate intranuclear spots at 8 hpi, but had accumulated in larger spots at the NE by 9 hpi
that persisted at 10 hpi (Figure 1B). Therefore, the isolation of NE and microsomal membrane (MM)
fractions was performed between 8 and 9 hpi from mock-infected and HSV-1 infected (MOI = 10) HeLa
cells. The fractions displayed a number of common and unique components (Figure 1C). Western
blotting revealed that Lamin A/C and LAP2β were only found in the NE fraction as expected, while
ER marker calnexin was predominantly in the MM fraction with some in the NE due to ONM-ER
continuity (Figure 1D). Neither NE nor MM fractions contained the Golgi marker GM-130, suggesting
low contamination with Golgi membranes involved in secondary envelopment (Figure 1E). Electron
microscopy of the isolated HSV-1 MMs revealed the expected membrane vesicles. Enveloped virus
particles were also captured in some vesicles as expected due to the contiguous nature of the NE and
ER (Figure 1F).
3.2. Host and Viral Proteins Identified in HSV-1 Infected MMs
MMs from HSV-1 infected cells and NEs and MMs from mock-infected cells were analyzed
by mass spectrometry using Multi-dimensional Protein Identification Technology (MudPIT)
LC/LC/MS/MS [30,31]. Due to the presence of virions (Figure 1F), HSV-1 proteins were identified
in the infected MMs. All but pUL17 were detected out of 8 viral proteins previously found in a
study of primary enveloped virions [42]. We identified pUL31 and its partner pUL34 (Tabls 1 and S1),
key players in primary envelopment. Other identified tegument proteins and glycoproteins included
gD, gB, gC all reported to associate with HSV-1 primary virions in different studies [43,44] with gB
being specifically implicated in ONM fusion during egress [15,16].
Gene ontology (GO) analysis of the proteins identified revealed many proteins with functions
in vesicle-mediated transport. Although this category reflects <4% of genes encoded in the human
genome, it represented 10% of all proteins detected in the MMs and 12% of all proteins detected in the
HSV-1 infected MMs. Moreover, when increasing selection stringency to look at only proteins enriched
in the HSV-1 infected MMs, the category jumped to 20% of total proteins. Because it also makes sense
scientifically that VFPs could have a potential role in HSV nuclear egress, we chose to pursue this
category. We increased selection stringency, only considering VFPs with at least 5 spectra in the NE
fraction to suggest that they are reasonably abundant in the NE before infection. We then plotted
the abundance ratio of these proteins in the HSV-infected:mock-infected MMs using dNSAF values,
a measure of abundance based on both spectral counts and percentage of total mass in the protein
fraction [36] (Figure 2A, Table 2). The ratios of NE:mock-infected MM dNSAF values were also plotted
(Figure 2B). It is noteworthy that, while the relative ratios are relevant here, it is not possible to compare
absolute amounts in the NE and MMs because of the differences in their volumes and because there
are much greater losses of membranes when isolating MMs. Though many VFPs identified would
potentially make sense to contribute to nuclear egress, VAPB was selected as a candidate for further
analysis because it was enriched in the NE compared to MMs, the most enriched VFP in HSV-1 infected
versus mock-infected MMs, and recently indicated to interact with the inner nuclear membrane protein
emerin in the IntAct Molecular Interaction Database “https://www.ebi.ac.uk/intact/”.
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are presented. (C) Domain structure of VAPB. The protein has an MSP domain that when mutated at
P56S causes a variant of amyotrophic lateral sclerosis (ALS8), followed by a coiled-coil domain that
precedes the C-terminal transmembrane domain. (D) Lysates from HSV-1 infected or mock-infected
HeLa cells were analyzed by Western blot for VAPB at different times post-infection. Quantification on
repeats for 3 time-points by Li-COR shown on the right revealed no change in VAPB levels during the
course of infection.
3.3. VAPB Expression and Localization During HSV-1 Infection
VAPB is a type II integral membrane protein previously characterized in the ER. Together with
family member VAPA, it is thought to function with cytoplasmic vesicle transport proteins and
cytoskeletal elements to maintain membrane structure and facilitate lipid transport, membrane
trafficking and membrane fusion [45]. VAPB is a C-terminally anchored protein with its primary
mass facing the cytoplasm in the ER (nucleoplasm for the inner nuclear membrane population) [46].
The N-terminal region has a major sperm protein (MSP) homology domain that interacts with FFAT
motif (two phenylalanines in an acidic track) proteins [47] followed by a coiled-coil domain before the
transmembrane segment (Figure 2C). A mutation (P56S) has been reported in the VAPB MSP domain
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causing an autosomal dominant form of amyotrophic lateral sclerosis (ALS8) that results in VAPB
aggregation and neurotoxicity [48].
VAPB-increased abundance in the infected MMs could be due to HSV-1-induced upregulation of
protein expression, virus-induced ER recruitment, or to increased abundance in the membranes due to
HSV-1 envelopment/de-envelopment. Total VAPB protein levels in the cell were constant during a
time course of infection (Figure 2D). VAPB has not previously been directly tested for a function in
the NE, but its initially reported restriction to the ER has been challenged [46,49–52]. To confirm a
NE location, a very specific monoclonal antibody was used (Figure 3A). In the mock-infected cells,
considerable ER distribution of VAPB was observed as well as a weak, but distinct rim around the
nucleus (defined by the DNA staining) and this staining was largely similar in infected cells (Figure 3B).
To identify infected cells, mock and HSV-1 infected cells were co-stained for VAPB and the herpesvirus
US3 protein. Next, an algorithm was employed that measured NE versus ER fluorescence and the
mean VAPB fluorescence signal intensities were calculated to identify any redistribution of VAPB
(Figure 3C). A small, but statistically significant increase in the NE pool was observed over the early
stages of infection. Over 50 cells were quantified for each condition and no difference was observed in
the NE:ER ratio of calnexin during HSV-1 infection. It is important to note, however, that the increase
in the NE covered a wide distribution, which might reflect different cells at different stages of infection
or might reflect shuttling of VAPB if it is being recycled for repeated use at the NE. Nonetheless, even
with the wide distribution, the data indicated the NE:ER ratio increasing from 1.18 to 1.80 between the
mock and 16 hpi conditions, respectively (Figure 3D). Finally, we tested for co-localization between
VAPB and NE-located pUL34. The majority of VAPB signal was in the ER while pUL34 concentrated
in the nucleus, but both gave clear nuclear rim staining in addition to staining in the ER with the NE
pool exhibiting partial overlap between the signals (Figure 3E). Lower left panels are blowups from the
above images, better showing the concentration of VAPB and pUL34 at the NE and that there are both
areas with a complete distinction between VAPB (red) and pUL34 (green) signals and yellow areas
where the signal overlaps. To quantify distribution, in the middle graph, each signal was quantified in
the NE as defined by the perimeter of the DNA staining and signal for the rest of the cell. For both
proteins, more signal was observed in the NE than in the rest of the cell. To quantify co-localization,
we used Pearson’s Correlation Coefficient to quantify overlap VAPB with pUL34 in the NE or the rest
of the cell. A much stronger correlation was observed for the NE signal than that in the rest of the cell.
The data suggest a partial recruitment of VAPB to the NE during HSV-1 infection.
3.4. Knockdown of VAPB Yields Significant Reduction of HSV-1 Viral Titers
To test the role of VAPB in virus replication, siRNA depletion followed by HSV-1 infection was
carried out. Rab24, a regulator of intracellular trafficking, was used as a negative control because
it did not increase in HSV-1 infected MMs compared to mock-infected MMs. Rab1a was used as a
positive control because this protein, required for ER-to Golgi complex transport [53], is involved in
HSV-1 mature particle assembly (secondary envelopment) and its knockdown reduces viral growth
by 60% [54]. Western blotting showed that VAPB was depleted to nearly undetectable levels and
both controls were knocked down by roughly 80% (Figure 4A). As expected [55], Rab24 knockdown
had little effect on viral titers while Rab1a knockdown reduced cell-released viral titers by 62%:
VAPB exhibited an even stronger reduction in cell-released virus titers of >90% (Figure 4B). These
were specific effects of the siRNAs as rescue experiments yielded nearly full recovery of virus titers
(Figure 4C). Similar to Rab1a, VAPB depletion resulted in a marked reduction in cell-associated virus
titers (<80%) compared to control Rab24 (Figure 4D); yet, viral genomes were still abundantly produced
(Figure 4E). Moreover, these effects were not likely due to inhibition of production of viral proteins
as pUL34 and gC levels were not reduced in VAPB knockdown cells (Figure 4F). A multistep growth
curve (starting MOI = 0.1) revealed around a two log-fold difference between HSV-1 replication in
mock versus VAPB siRNA-treated cells (Figure 4G).
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by Western blot of HeLa cells. (B) HeLa cells were either mock infected or infected with MOI = 10
HSV-1 (WT). At 8 and 16 hpi, cells were fixed and processed for regular widefield immunofluorescence
microscopy with VAPB mouse monoclonal antibodies and rabbit US3 antibodies (to identify infected
cells). Some VAPB signal gave a distinct rim around the NE (indicated by arrowheads on one cell
in the top VAPB panel), though signal also appeared throughout the ER. Scale bar, 10 µm. (C) The
relative pixel intensities in the ER and NE were quantified. For each cell, five lines were drawn through
the middle of the nucleus and pixel intensity was measured at a point in the nuclear rim (based on
DAPI staining) and at a point 2 µm distant into the ER and the NE/ER ratio was calculated. Boxplots
from 30 cells are shown in the graph below the images with the median (central line) and the error
bars (grey) marked. Each sample was compared with its control (mock cells) by one-way ANOVA
analysis followed by the Holm-Sidak’s multiple-comparison test. Significant p-values (**** p ≤ 0.0001)
illustrate the general trend of these vesicle fusion proteins to accumulate at the NE upon infection.
(D) Separately, after defining the NE in relation to the DAPI signal, the total NE fluorescence and all
fluorescence signal outside the nucleus was quantified. From this data, mean fluorescence intensities
from the whole NE and ER in sections were quantified, the ratios of NE:ER signal were determined,
and their distribution was plotted using a log scale. This further revealed a wide distribution of NE:ER
ratios in the infected cells compared to a tight distribution for the mock infected. The shift change
in distribution with HSV-1 infection was still significant using a pair-wise Dunn test: **** p < 0.0001.
(E) Microscopy images of cells co-stained with VAPB and pUL34 antibodies. Z-stacks of images were
taken using 0.2 µm steps and then deconvolved. Images shown are from individual sections. Zoom
images are shown in the bottom left corner of the panel with the scale bar for the upper image 10 µm
and that for the zoomed images 2.5 µm. The first graph is from quantifying the mean pixel intensity
in the NE compared to that in all other regions of the cell (including the nuclear interior), using the
DAPI stained DNA to define the nuclear edge. The standard deviation of the mean is shown and
paired t tests confirmed significance: *** p < 0.001; **** p < 0.0001 The graph in the right corner plots the
Pearson’s Correlation Coefficient for the overlap between VAPB and pUL34 signal in the NE and in the
other regions of the cell. Standard deviations are shown along with the distribution of values.
3.5. VAPB Knockdown Yields Reduced Cytoplasmic Virus Particles and Nuclear Particle Accumulation
Viral titer reduction could reflect a function of VAPB in nuclear egress or secondary envelopment
or cytoplasmic transport. Examination by electron microscopy of HSV-infected, and control- or
Rab24-depleted cells revealed the expected distribution with many virus particles present both in
the nucleus and in the cytoplasm at 16 hpi (Figure 5A, upper panels). However, VAPB knockdown
resulted in more nuclear and less cytoplasmic virus particles compared to control siRNA-treated
cells (Figure 5A, lower panels). Images focused on the cytoplasm revealed far fewer cytoplasmic
particles in the VAPB-depleted cells (Figure 5B). Quantification of particles in the nucleoplasm, the
NE and the cytoplasm revealed an increase in nucleoplasmic and NE virions with a corresponding
reduction in cytoplasmic virions in VAPB knockdown cells (Figure 5C,D). Several images revealed
enveloped particles in lumenal extensions of the NE and the presence of the virus envelope could
clearly be distinguished by size from the un-enveloped particles in the nucleoplasm (Figure 5A, lower
right panel). Note that the NE lumen is similarly enlarged by accumulating virus particles in US3
deletions [12,13].
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established on U2OS cells and bars represent the average of three independent experiments, 
normalized to the control siRNA. Error bars are to the standard deviation and the p‐values using a 
one‐way ANOVA and multiple comparisons by Dunnett's test for comparing each condition with the 
control are shown (* p ≤ 0.05; **** p ≤ 0.0001). (C) Rescue experiments with cells expressing wild‐type 
protein resistant to the siRNAs were performed and supernatant virions also collected at 16 hpi. In all 
cases, the cells carrying both the rescue plasmid and the siRNAs recovered to roughly 80–90% of the 
control virus titers. Error bars are to the standard deviation and the p‐values using a one‐way 
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are shown (** p ≤ 0.01; **** p ≤ 0.0001). (D) After 48 h, HeLa cells transfected with the siRNAs were 
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Rab24 siRNA, used as a control to better parallel background knockdown effects compared to non‐
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Figure 4. VAPB knockdown inhibits HSV-1 infection. (A) HeLa cells were transfected with siRNA oligos
for VAPB and controls and cells lysed after 48 h. Western blot confirmed knockdowns. Quantification
from three experiments is given in the right panel: error bars are to the standard deviation and the
p-values using a one-way ANOVA and multiple comparisons by Dunnett’s test for comparing each
condition with the control are shown (** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001). (B) HeLa cells were
transfected with the control, Rab24, Rab1a, or VAPB siRNAs. After 48 h, cells were infected with HSV-1
(MOI = 10) and supernatant virions were collected at 16 hpi. Titers were established on U2OS cells and
bars represent the average of three independent experiments, normalized to the control siRNA. Error
bars are to the standard deviation and the p-values using a one-way ANOVA and multiple comparisons
by Dunnett’s test for comparing each condition with the control are shown (* p ≤ 0.05; **** p ≤ 0.0001).
(C) Rescue experiments with cells expressing wild-type protein resistant to the siRNAs were performed
and supernatant virions also collected at 16 hpi. In all cases, the cells carrying both the rescue plasmid
and the siRNAs recovered to roughly 80–90% of the control virus titers. Error bars are to the standard
deviation and the p-values using a one-way ANOVA and multiple comparisons by Dunnett’s test for
comparing each condition with the control are shown (** p ≤ 0.01; **** p ≤ 0.0001). (D) After 48 h,
HeLa cells transfected with the siRNAs were infected with HSV-1 (MOI = 10) and cell pellets collected
at 16 hpi. Titers were established on U2OS cells and bars represent the average of three independent
experiments, normalized to the data for Rab24 siRNA, used as a control to better parallel background
knockdown effects compared to non-target siRNA. Error bars are to the standard deviation from two
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separate experiments and the p-values using a pair-wise test (Tukey) to compare each condition with
the Rab24 control are shown (** p ≤ 0.01; specifically for Rab1a p = 0.001938 and for VAPB p = 0.003162).
(E) Total genome copies for cell-associated virus were determined by qPCR. (F) Levels of HSV-1 pUL34
and gC1 protein were determined by Western blot between the control siRNA and VAPB knockdown
cells. The housekeeping protein GAPDH was used as a loading control. (G) HeLa cells were transfected
with either a control siRNA or siRNA against VAPB. A multistep HSV growth curve over 48 h was
performed by infecting cells at MOI = 0.1 in triplicate. Samples were harvested at the indicated times.
Titers were determined by plaque assay using U2OS cells.Cells 2019, 8, x FOR PEER REVIEW  17 of 30 
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absence from the cytoplasm with VAPB knockdown. In all images, the nucleus is at the top of the panel.
(A) In control and Rab24 knockdown cells, some non-enveloped virus particles could be observed in
the nucleoplasm (one example shown for each upper image with downward facing arrowheads), but
many enveloped and non-enveloped particles could also be observed in the cytoplasm (one example
shown for each upper image with upward facing arrowheads) as well as released mature particles
just outside the cell (a large accumulation of these is highlighted with the angled arrow in the upper
right image). In contrast, for the VAPB knockdown, few particles could be seen in the cytoplasm
and visibly more nucleoplasmic non-enveloped particles were observed. In a zoomed image, several
particles that had acquired a primary envelope were observed for the knockdowns in the NE lumen
(two sets of multiple virus particles indicated by arrows). A single arrowhead highlights an assembled
virus nucleocapsid prior to envelopment to contrast for particle size at the different stages. (B) Images
focused more on the cytoplasm reveal virus particles in the cytoplasm for the siRNA control but a
relative dearth of viral particles in the cytoplasm for the VAPB knockdown. Scale bars, 1 µm. (C) Over
1400 virus particles were counted for each condition and the percentages of nuclear, peri-nuclear (NE
lumen), and cytoplasmic particles is given. Virus particles specifically accumulated in the nucleus
and peri-nuclear lumen with VAPB knockdown. (D) Plotting the log2 ratio of nuclear:cytoplasmic
virus particles for each condition revealed an inversion in the nuclear:cytoplasmic ratio where from
particles being slightly more in the cytoplasm for the siRNA and Rab24 knockdown controls they
became predominantly nuclear for the VAPB knockdown. Use of the Fisher’s exact test reveals very
significant differences from the control (**** p < 0.0001; ***** p < 1 × 10−50).
Next, we tested for capsid protein VP5, which in a normal infection generally appears
predominantly at the nuclear periphery and aggregates in the cytoplasm because of the rapid trafficking
of assembled virions from the nucleus [56]. This is the pattern observed for control siRNA cells, while
the VAPB knockdown cells show a strong accumulation of the VP5 in the nucleus (Figure 6A). We also
used fluorescence in situ hybridization (FISH) and viral DNA qPCR to quantify viral genomes. Infected
cells with control and VAPB knockdowns were fixed and hybridized with a probe for the HSV-1 ICP27
gene. Pre-treatment with RNase ensured only viral genomes would be recognized. A proportion of
nuclear virus genomes will not be encapsidated and this approach will also detect them; however,
the aim was to determine egress to the cytoplasm by measuring fluorescent viral genome signals
in both the nucleus and cytoplasm. Co-staining with DAPI identified the nuclear boundaries and
imaging revealed virus accumulating in the cytoplasm in non-target siRNA control cells, the Rab24
knockdown, and in cells depleted of Rab1a that affects HSV-1 egress in the cytoplasm (Figure 6B).
By contrast, in the VAPB knockdown, the FISH signal for viral genomes was visually restricted to the
nucleus (Figure 6B). Images for this analysis were taken from the nuclear midplane where nuclear area
is greatest. While generally the ER sectional area is also greater at the nuclear midplane, it is possible
that changes induced by the HSV-1 infection that alter both ER and Golgi membrane distribution
might yield a skewed distribution for the positioning of virus particles. Nonetheless, all samples were
treated equally and so the differences between the VAPB knockdown and control samples should still
be relevant. The intensity of total FISH signal in each cell, and also that just in the nucleus (using the
DAPI staining as a mask) was determined. The total signal divided by the nuclear signal was plotted
so that the amount of signal outside the nucleus is reflected in values above 1 (Figure 6C). All three
controls exhibited a clear cytoplasmic signal while VAPB knockdown had a value close to 1, indicating
mainly nuclear signal. Interestingly, some accumulation of virus genomes at the NE could be observed
in the VAPB knock-down (Figure 6D). Next we quantified DNase-resistant viral DNA (encapsidated
genomes) in the nucleus of HSV-infected cells with or without siRNA depletion. Figure 6E shows
a significant increase in DNase-resistant viral genome copies (4.5-fold) when VAPB was depleted
compared to control Rab24. Rab1a depletion resulted in more DNase-resistant nuclear genome copies
than the control, but this difference was not statistically significant.
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red line so that a portion of the VP5 in the nucleus can be observed in the control knockdown cells,
as expected. (B) The virus gene ICP27 was used as a FISH probe and labeled with biotin. Cells were
knocked down for VAPB and controls Rab24, Rab1A and non-target siRNA, infected with HSV-1 and at
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16 hpi fixed and processed for FISH. The hybridized virus ICP27 gene was visualized with streptavidin
conjugated to Alexa488 dye and imaged by immunofluorescence microscopy. Cells were co-stained
with DAPI to identify the nucleus. Images were taken at the midplane of the nucleus to minimize
any signal from above or below the nucleus. This tends to also maximize the sectioned area of the
ER/Golgi. Scale bar, 10 µm. (C) Using the DAPI nuclear staining to generate a mask of the nuclear
area, the nuclear pools of hybridized virus ICP27 DNA were quantified from roughly 50 cells for each
condition. Our previous studies on genome organization have shown that this 2D analysis is sufficient
to see differences revealed by more intensive 3D imaging. The total hybridized ICP27 DNA in the
same cell was also quantified and plotted divided by the nuclear signal so that values above 1 reflect
the cytoplasmic pool of viral genomes. A clear increase in cytoplasmic viral genomes can be seen
for the non-target siRNA control, the Rab24 and the Rab1A knockdowns, while no notable increase
in cytoplasmic viral genomes was observed for VAPB knockdown. Statistical measurements were
performed using a 2-tailed ANOVA analysis: *** p < 0.001. (D) The same images of cells analyzed for
FISH were also counted for the visible accumulation of viral genome signals at the NE. The percentage
is plotted and statistical significance from Fisher’s Exact test is given as: * p < 0.05. (E) In a separate
experiment, DNase-resistant viral genomes were isolated by preparing nuclei from HSV-infected cells
(MOI = 10, 16 hpi) following siRNA knock down. Nuclei were disrupted and incubated with DNase
to remove unencapsidated DNA. DNA was prepared using a QIAamp DNA purification kit with
RNase treatment to remove viral mRNAs. Remaining viral DNA was quantified by qPCR. Increases
in encapsidated viral DNA of greater than 4-fold were observed upon siRNA depletion of VAPB, but
not the control, Rab24. The data are from a single experiment and standard deviations and statistics
are generated from three technical replicates with an ANOVA of p = 5.6 × 10−05: pair-wise Tukey test
** p < 0.01.
3.6. VAPB Knockdown Does Not Interfere with Virus Protein Accumulation at the NE
VAPB knockdown was previously reported to interfere with NE targeting of NPC proteins gp210
and Nup214 and the INM protein emerin [38]; thus, its knockdown could potentially interfere with
INM accumulation of pUL34 that is essential for primary envelopment. To test if VAPB indirectly
alters egress, we stained for pUL34 in HSV-1 infected VAPB-depleted cells (Figure 7A). No notable
difference was observed in pUL34 distribution between control (siCntl) and the VAPB knockdowns.
NE rim staining for pUL34 was observed in individual cells with strong VAPB knockdown. These data
show that VAPB contributions to nuclear egress are not indirect effects on the distribution of the most
critical viral proteins involved in this step.
Confocal and EM images did not indicate major changes in the NE upon VAPB depletion. In case
VAPB depletion resulted in gross changes to other cellular membranes that might affect HSV cellular
egress, we determined the location of calnexin, an ER marker, and GM-130, a Golgi marker (Figure 7B).
The pattern of staining with antibodies against either protein was generally similar between control
and VAPB depleted cells, suggesting that VAPB depletion does not affect the gross structure of other
membranous compartments though minor effects on Golgi structure and function remain possible.
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3.7. VAPB Is Present on the NE and in Association with Viral Particles
Immunogold labelling electron microscopy was used to visualize VAPB in the NE. Although
typically only 3–5 particles were observed in a NE region captured in a particular section, nearly
all images examined had particles in both INM and ONM in both the mock-infected and HSV-1
infected cells (Figure 8A,B). As expected, particles were also observed in association with the ER
(Figure 8A, ER membrane delineated by arrowheads). Importantly, some virus particles inside nuclear
invaginations that appear to be luminal extrusions contained VAPB-labelled gold particles (Figure 8C).
These generally displayed tightly packaged genomes, an apparent envelope, and were proximal to
other cellular membranes and DNA, suggesting that they are primary enveloped particles captured
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in the NE lumen. The image in Figure 8D shows a particle that is clearly in the NE lumen (L). Other
sections that appear to be glancing sections at the nuclear surface often contained many virus particles
with less densely packaged genomes associating with VAPB-labelled gold particles (Figure 8E). The
staining for VAPB on nuclear virus particles suggests the possibility that VAPB participates in the
process of primary envelopment.
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visible ER membranes, many in association with gold particles, are indicated with arrowheads. (B) 
Quantification of 206 and 163 VAPB‐labelled gold particles at the NE from respectively the mock 
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particles associated with different parts of the nuclear membrane are plotted. Notably, a reasonable 
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Figure 8. V PB accu ulates in both the ONM and INM and associates with virus particles. HeLa cells,
either mock infected or infected with WT HSV-1 MOI = 10, were fixed at 16 hpi and cryosectioned prior
to labelling with VAPB mouse monoclonal antibodies and anti-mouse conjugated gold particles for
electron microscopy. (A) Mock infected cells (left panels) and HSV-infected cells in areas lacking virus
particles (right panels) to investigate the membrane localizations of VAPB. In all panels, the cytoplasm
is on the top and the nucleoplasm is on the bottom with this labeled in the upper left panel by C and
N, respectively, and nuclear pore complexes in the top panels are labelled NPC. The upper left panel
also contains two arrows that face towards the ONM and INM. A subset of visible ER membranes,
many in association with gold particles, are indicated with arrowheads. (B) Quantification of 206 and
163 VAPB-labelled gold particles at the NE from respectively the mock infected and HSV-1 infected
populations using 81 images each. The percentage of total NE gold particles associated with different
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parts of the nuclear membrane are plotted. Notably, a reasonable number of VAPB-labelled gold
particles were observed in all membrane compartments: ONM, INM, NE lumen, and pore membrane
with the NPC. Note that counted luminal particles may reflect sectioning angles where the gold particle
artificially appears to be on the other side of the membrane, but as this cannot be ascertained for
certain, they were counted separately. (C) Left: high magnification images of primary enveloped HSV-1
particles (PEPs) with VAPB-labelled gold particles that appear to be in membrane-bound invaginations
of the NE. In the left image, the arrow points to the viral envelope and the arrowheads point to areas
where the membrane of the invagination can be distinguished with N and C demarcating the nuclear
and cytoplasmic compartments. The invaginated membrane also is associated with gold particles. (D)
An enveloped HSV particle with VAPB-labelled gold particles clearly inside the NE lumen. In addition
to the N and C demarcating the nuclear and cytoplasmic compartments, the INM and ONM are
also highlighted by arrowheads facing one another. (E) Nuclear virus particles that appear to lack
an envelope in association with VAPB-labelled particles. The sections have the appearance of being
glancing sections at the surface of the nucleus. The two arrows in the left panel indicate gold particles
associating with virus particles. All scale bars are 100 nm.
4. Discussion
It has been proposed that host cell proteins could play a role in primary envelopment and nuclear
egress [21] and such a role for several host proteins has already been indicated. During HSV-1 infection
activated protein, kinase C is recruited to the nuclear membrane, where it phosphorylates and remodels
the nuclear lamina to facilitate primary envelopment [57]. p32 is a cellular protein that can interact
with a number of herpesvirus proteins and in HSV-1 infection, it is recruited to the nucleus/nuclear
rim by ICP27 and ICP34.5 [23,58], but may play a role in nuclear egress via interaction with tegument
protein UL47 [24]. Two proteins, CD98 and β-integrin, can act as regulatory proteins in the case of
fusion of enveloped viruses with the plasma membrane [59–62] but during HSV-1 infection, they can
also be recruited to the nuclear membrane where, through interaction with key viral proteins including
UL31 and US3, they may indirectly control de-envelopment [22].
Our approach to identifying additional cellular proteins was to examine changes in the proteome
of NE and ER membranes comparing HSV-1 infected and mock infected HeLa cells. While there
are many proteins that might change in levels due to HSV-1 infection or relocate to these membrane
compartments for other reasons as a consequence of HSV-1 infection, it is likely that within the set
of changing proteins would also be those involved in egress. This is because participation in egress
requires first a physical presence in the NE and any INM proteins captured in the primary envelope
would enter the ONM upon fusion, from whence they could diffuse into the ER. Thus, while proteins
fulfilling these criteria would not necessarily be involved in egress, it is likely that a subset would.
Therefore, this approach was used to identify candidates to be further tested for possible functions
in egress. Interestingly, VFPs comprised of a key protein group whose presence in the NE/ER was
significantly increased during HSV-1 infection. In particular, among roughly 50 VFPs identified in the
NE, only a few exhibited the expected characteristics, thus identifying as a candidate VAPB, an ER
resident protein whose levels do not change during HSV infection and which we found to be largely
required for HSV-1 replication. It facilitates cytoplasmic viral particle accumulation, localizes to the NE
in association with primary enveloped virions and co-locates with viral nuclear egress protein pUL34.
These data suggest a role for VAPB in HSV-1 nuclear egress. Although exogenous overexpression of
viral pUL31/34 proteins promotes formation of NE vesicles and their in vitro expression can bend
membrane vesicles [10,11], it seems likely that during infection vesicle fusion, proteins could be used
to make egress more efficient. Herpesviruses frequently co-opt host cell machinery to support various
aspects of their life cycle [17,18] and ESCRT pathway proteins were recently shown to be involved in
nuclear egress of Epstein-Barr virus (EBV) [63]. In this case, the Chmp4b protein important for scission
complex assembly co-localized in perinuclear aggregates with EBV protein BFRF1 and inhibition of the
Alix bridging protein yielded capsid protein accumulation in the nucleus [63]. Notably these proteins
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were not required for HSV-1 egress, suggesting that other host cell vesicle trafficking proteins function
instead of the ESCRTs for this virus.
VAPB is a member of the Vesicle-associated membrane protein (VAMP)-Associated Protein family
of C-terminal tail anchored proteins. It has been shown to function as an adaptor to recruit target
proteins to the ER and execute cellular functions such as lipid transport, membrane trafficking and
membrane fusion [45]. It also functions in calcium homeostasis and has an additional mitochondrial
function reported [49,52]. An indirect NE link was reported for VAPB, where its knockdown resulted
in reduced NE accumulation of NPC proteins gp210 and Nup214 and the INM protein emerin [38].
However, it was thought that this reflected an indirect consequence of VAPB knockdown, inducing
Golgi fragmentation and disruption of ER to ERGIC (ER-Golgi Intermediate Compartment) to Golgi
trafficking [64,65]. As we found clear VAPB accumulation in the NE, these data might be re-interpreted
to consider a nuclear membrane trafficking role and/or a role in fusion events during NE assembly
at the end of mitosis. The latter is consistent with the ESCRT proteins shown to be involved in EBV
nuclear egress also functioning in NE reformation after mitosis [66]. Our data are also consistent with
a potential direct function in nuclear egress as VAPB knockdown did not block NE accumulation
of pUL34. This does not discount, however, the possibility of VAPB having an additional role in
secondary envelopment.
A critical outstanding question is whether VAPB contributes to primary envelopment or
de-envelopment or both during nuclear egress. Immunogold EM labelling revealed VAPB in
association with nucleoplasmic/luminal virions in a membranous vesicle and, together with the
nucleoplasmic accumulation of virus particles, this suggests a role in primary envelopment. As VAPB
is in both the INM and ONM according to the immunogold EM data, it could potentially contribute
to both primary envelopment and de-envelopment; however, the topology of VAPB is such that its
principal functional mass should be facing the nucleoplasm in the INM and the cytoplasm in the
ONM. Thus, it is perfectly poised to potentially interact with virus nucleocapsids during primary
envelopment, but it should not be positioned to interact with the primary enveloped particles in the
nuclear envelope lumen in order to initiate fusion with the ONM for de-envelopment unless, as has
never been tested, it assumes a different topology during HSV-1 infection. Nonetheless, once the initial
fusion has begun, VAPB either in the primary envelope or in the ONM could potentially be positioned
to contribute to stabilizing and/or completing the process of nuclear egress. Likewise, and perhaps
more likely, the separate role reported for VAPB in calcium homeostasis could lead to indirect effects on
the fusion step [49,52]. In considering a potential de-envelopment function for VAPB, it is noteworthy
that previous studies of HSV-1 US3, gB and gH depletion or mutants revealed an accumulation of
primary enveloped particles in both the nucleoplasm and in the NE lumen, the expected phenotype for
a role in the de-envelopment phase of nuclear egress [12,13,15,16] and, similarly, both nucleoplasmic
and luminal viral particle accumulation were observed with VAPB knockdown. However, further
experiments are required to identify the precise stage at which VAPB acts, and these are ongoing.
A potential function for VAPB in nuclear egress does not contradict recent papers arguing that
pUL31 and pUL34 are sufficient for primary envelopment, as these studies showed induction of
membrane invaginations in vitro in one study [10] and in context of a cell still containing VAPB
in the other [11], while not addressing the issue of efficiency compared to a wild-type infection.
Though with greatly reduced titers, HSV-1 has been shown to still get out of the nucleus in the
absence of pUL31/34 [12–14,67,68]. Nonetheless, as pUL31/34 are central proteins for nuclear egress,
it will be important to determine if VAPB contributions to nuclear egress result from participating
in functions with or independent of these critical viral proteins. Thus far, our efforts to test for an
interaction between VAPB and pUL34 have been negative; however, VAPB could also interact with
HSV-1 capsid/tegument proteins or contribute in as yet undetermined ways. The lack of clarity in
the composition of primary enveloped particles allows for a very wide range of potential partners,
so this may be a significant undertaking in the future. If VAPB interacts with virus proteins, it could
also provide a mechanism for specific recruitment of VAPB to egress complexes; however, it is also
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possible that HSV-1 disruption of ER and Golgi membranes unintentionally results in a redistribution
of VAPB where it can indirectly contribute to nuclear egress and it remains possible that the trafficking
of some important player in nuclear egress besides pUL34 is not able to gain access to the NE in the
VAPB knockdown cells.
The demonstration of significant defects in virus nuclear egress for the VAPB knockdown suggests
that other of the VFPs similarly highlighted by our study might also be involved in HSV-1 nuclear
egress. This idea is more compelling by the general functioning of VFPs in larger complexes and
observations that VAPB itself interacts with other proteins identified or closely related proteins. For
example, Rab11, which was also highlighted by our mass spectrometery analysis, functions in a
complex with VAPB and several other proteins [69,70]. Separately VAPB has been shown to interact
with VAMP1 and 2 [51], both members of the same family, as VAMP7 that was similarly highlighted in
our mass spectrometry analysis. Moreover, the IntAct Molecular Interaction Database [71] reveals that
VAMP7 is involved in several different vesicle membrane trafficking complexes including multiple
SNARE complexes, one of which includes Stx7 that was also highlighted by our mass spectrometry
analysis. Compellingly, IntAct also reveals VAPB interactions with the inner nuclear membrane protein
emerin and multiple virus proteins from Hepatitis C Virus [72].
A study reporting co-localization of gB, gH, pUL31 and pUL34 at the NE together with cellular
proteins CD98hc and β1-intergrin argued for formation of a complex with a role in HSV nuclear
de-envelopment [22]. Just as the viral proteins in that study might co-opt host cellular proteins, we
postulate that VAPB forms part of a larger egress complex together with viral proteins [73]. The
reduction in cytoplasmic particles and virus titers with VAPB knockdown and the labelling of virus
particles with VAPB antibodies strongly argues that VAPB is directly involved in HSV-1 nuclear egress.
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